Business Standard
Saturday, Feb 18, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Commodities
 

UAE drug firm gets nod for production of swine flu medicine
Press Trust of India / Dubai Sep 28, 2009, 12:21 IST

Abu Dhabi-based drug manufacturer Neopharma today said it has received clearance from the UAE Ministry of Health for the production of an antiviral medication Oseltamivir BR Flu.

The approval comes at a time when the entire region is stepping up efforts to tackle the swine flu pandemic, and it is being considered as a potential choice to prevent and treat the disease.

Neopharma, Vice-Chairman, Abdulla Humaid Al Mazroei and Managing Director and CEO, Dr BR Shetty thanked the Health Ministry on behalf of the Board of Directors of the company.

"As a leading manufacturer of life-saving drugs, we believe it is our responsibility to play a vital role in helping the community at this critical juncture. We are confident the approval for Oseltamivir will significantly facilitate medical professionals and the wider community to effectively combat the lethal H1N1 virus in the region," Dr Shetty said.

Neopharma's Oseltamivir BR Flu is the outcome of a joint venture with leading pharmaceuticals major Hetero Drugs Ltd, and is the first in a series of major life-saving drugs which the company plans to produce over the next few years.

Currently, Neopharma has independent production blocks for the manufacture of general and betalactam products. The company's plant in Abu Dhabi is designed for the large-scale production  of tablets, capsules and liquid orals.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- Wall Street up on Greece, but gains seen limited
- FII-TO-FII: Pantaloon traded at 7% premium
- Civic polls: Saffron alliance retains Mumbai, Thane
- MCX awaits trading rules in commodity options, indices
- Govt to provide incentives for electronic chip manufacturing
  Read Business news in 
- Now property search gets more exciting than ever before!
- High Growth Business Opportunities in Africa - Register to explore
- Medium-sized businesses are the engines of a smarter planet.
- Save over Rs.3000 with IndianOil Citibank Card
- India's No. 1 Property Site. Click here to know more..
- Get 5% cashback on telephone bills with Citi
- Diseases earlier, Saving Costs, Extending Lives. Know More..
- Enjoy the journey as much as the destination. click to know more..
- Exim Bank Conclave on India - Africa Project Partnership. Know more..
- Creating Wealth made simple the SIP way. Know more..
- Only Developer to give a guarantee on time space & rate.
- Office 365 for professionals and small businesses.
- Buy Your Property with Our Triple Guarantee in India.
- Improve Patient Care & Experience. Click here to know more
- Win a Business Class Ticket to Europe..Know more..
-  Introduce a New Automotive Luxury Car.. know more
Sorry, comments to this story are closed
Latest Messages
SmartInvestor+ E-zine
  Pay Rs.747/- for 3 years and
  get a branded watch FREE

  Subscribe Now
Most Popular
Read
E-Mailed
Commented
   
- T N Ninan: Saving Mumbai
- Aditi Phadnis: The battle lines for Behenji
- Deepak Lal: Rights, stakes and Newspeak
- The malt of India
- Lehman withdraws winding-up petition against Wockhardt
 
 More  
BUSINESS STANDARD INDIA 2012
  Now available at Special price
  Rs.395/- Only
  Buy Now
  Now available on the Kindle Store...
  BS Specials  
    Full coverage of elections in Uttar Pradesh, Punjab, Uttarakhand, Manipur and Goa
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us